DOCSLIB.ORG

Interactions with Nnrtis Charts Revised June 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interactions with Nnrtis Charts Revised June 2019 www.hiv-druginteractions.org Interactions with NNRTIs Charts revised June 2019. Full information available at www.hiv-druginteractions.org Page 1 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. + + EFV ETV EFV ETV NVP RPV NVP RPV DTG DTG DOR DOR F/TAF F/TAF RPV + RPV + RPV + RPV + DOR DOR 3TC/TDF 3TC/TDF Anaesthetics & Muscle Relaxants Antibacterials Alcuronium Amikacin Bupivacaine Amoxicillin Cisatracurium Ampicillin Desflurane Azithromycin Dexmedetomidine Bedaquiline Enflurane Capreomycin Ephedrine Cefalexin Halothane Cefazolin Isoflurane Cefixime Ketamine Cefotaxime Nitrous oxide Ceftazidime Propofol Ceftriaxone Rocuronium Chloramphenicol Sevoflurane Ciprofloxacin Sufentanil Clarithromycin Suxamethonium (succinylcholine) Clavulanic acid Tetracaine Clindamycin Thiopental Clofazimine Tizanidine Cloxacillin Vecuronium Cycloserine Analgesics Dapsone Alfentanil Delamanid Aspirin Doxycycline Buprenorphine Ertapenem Celecoxib Erythromycin Codeine distribution. for Not only. use r personal Ethambutol Dextropropoxyphene Ethionamide Diamorphine (diacetylmorphine) Flucloxacillin Diclofenac Gentamicin Dihydrocodeine Imipenem/Cilastatin Fentanyl Isoniazid Hydrocodone Kanamycin Hydromorphone Fo istribution. Levofloxacin Ibuprofen Linezolid Mefenamic acid Meropenem Methadone Metronidazole Morphine Moxifloxacin Naproxen Nitrofurantoin Nimesulide Ofloxacin Oxycodone Para-aminosalicylic acid Paracetamol (Acetaminophen) Penicillins Pethidine (Meperidine) Pyrazinamide Piroxicam Rifabutin Tapentadol Rifampicin Tramadol Rifapentine Anthelmintics Rifaximin Albendazole Spectinomycin Diethylcarbamazine Streptomycin Ivermectin Sulfadiazine Levamisole (Ergamisol) Telithromycin Mebendazole Tetracyclines Niclosamide Trimethoprim/Sulfamethoxazole Oxamniquine Vancomycin Praziquantel Anti-coagulant, Anti-platelet and Fibrinolytic Pyrantel Acenocoumarol Suramin sodium Apixaban Triclabendazole Argatroban Antiarrhythmics Aspirin (anti-platelet) Amiodarone Betrixaban Bepridil Clopidogrel Disopyramide Dabigatran Dofetilide Dalteparin Flecainide Dipyridamole Lidocaine (Lignocaine) Edoxaban Mexiletine Eltrombopag Enoxaparin Propafenone for d Not only. use For personal for distribution. only. Not use For personal Quinidine Fondaparinux Heparin Phenprocoumon Prasugrel Rivaroxaban Streptokinase Ticagrelor Warfarin Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. DOR Doravirine (Pifeltro®) RPV Rilpivirine (Edurant®) These drugs should not be coadministered DOR + Doravirine + RPV + Rilpivirine + © Liverpool Drug Interaction Group, University of Liverpool 3TC+ Lamivudine+Tenofovir-DF DTG Dolutegravir Potential interaction – may require close monitoring, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® ® TDF (Delstrigo ) (Juluca ) alteration of drug dosage or timing of administration EFV Efavirenz RPV + Rilpivirine + We aim to ensure that information is accurate and consistent with current knowledge and practice. ®, ® Potential interaction likely to be of weak intensity. (Sustiva Stocrin ) F/TAF Emtricitabine + However, the University of Liverpool and its servants or agents shall not be responsible or in any Additional action/monitoring or dosage adjustment is Tenofovir alafenamide way liable for the continued currency of information in this publication whether arising from ® unlikely to be required ETV Etravirine (Intelence ) (Odefsey®) negligence or otherwise howsoever or for any consequences arising therefrom. The University of ® Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent NVP Nevirapine (Viramune ) No clinically significant interaction expected permitted by law. www.hiv-druginteractions.org Interactions with NNRTIs Charts revised June 2019. Full information available at www.hiv-druginteractions.org Page 2 of 5 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. + + + + EFV ETV EFV ETV NVP RPV NVP RPV DTG DTG DOR DOR F/TAF F/TAF RPV RPV + RPV RPV + DOR DOR 3TC/TDF 3TC/TDF Anticonvulsants Antifungals Carbamazepine Amphotericin B Clonazepam Anidulafungin Eslicarbazepine Caspofungin Ethosuximide Fluconazole Gabapentin Flucytosine Lacosamide Griseofulvin Lamotrigine Itraconazole Levetiracetam Ketoconazole Oxcarbazepine Miconazole Phenobarbital (Phenobarbitone) Nystatin Phenytoin Posaconazole Pregabalin Terbinafine Primidone Voriconazole Tiagabine Antihistamines Topiramate Astemizole Valproate (Divalproex) Cetirizine Vigabatrin Chlorphenamine Zonisamide Diphenhydramine Antidepressants Fexofenadine Agomelatine Levocetirizine Amitriptyline Loratadine Bupropion Promethazine Citalopram Terfenadine Clomipramine Antimigraine Agents Desipramine Almotriptan Doxepin distribution. for Not only. use r personal Dihydroergotamine Duloxetine Ergotamine Escitalopram Rizatriptan Fluoxetine Sumatriptan Fluvoxamine Antiprotozoals Imipramine Amodiaquine Lithium Artemisinin Maprotiline Fo istribution. Atovaquone Mianserine Benznidazole Milnacipran Chloroquine Mirtazapine Diloxanide Nefazodone Eflornithine Nortriptyline Halofantrine Paroxetine Lumefantrine Phenelzine Mefloquine Reboxetine Meglumine antimoniate Sertraline Melarsoprol Tranylcypromine Miltefosine Trazodone Nifurtimox Trimipramine Paromomycin Venlafaxine Pentamidine Vortioxetine Piperaquine Anti-diabetics Primaquine Acarbose Proguanil Canagliflozin Pyrimethamine Dapagliflozin Quinine Dulaglutide Sodium stibogluconate Empagliflozin Sulfadoxine Exanatide Antipsychotics/Neuroleptics Glibenclamide (Glyburide) Amisulpride Gliclazide Aripiprazole Glimepiride Asenapine Glipizide Chlorpromazine Insulin Clozapine Linagliptin Fluphenazine Liraglutide Haloperidol Metformin Iloperidone Nateglinide Levomepromazine Pioglitazone Olanzapine Repaglinide Paliperidone Rosiglitazone for d Not only. use For personal for distribution. only. Not use For personal Perazine Saxagliptin Periciazine Sitagliptin Perphenazine Tolbutamide Pimozide Vildagliptin Pipotiazine Quetiapine Risperidone Sulpiride Thioridazine Tiapride Ziprasidone Zotepine Zuclopenthixol Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. DOR Doravirine (Pifeltro®) RPV Rilpivirine (Edurant®) These drugs should not be coadministered DOR + Doravirine + RPV + Rilpivirine + © Liverpool Drug Interaction Group, University of Liverpool 3TC+ Lamivudine+Tenofovir-DF DTG Dolutegravir Potential interaction – may require close monitoring, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® ® TDF (Delstrigo ) (Juluca ) alteration of drug dosage or timing of administration EFV Efavirenz RPV + Rilpivirine + We aim to ensure that information is accurate and consistent with current knowledge and practice. ®, ® Potential interaction likely to be of weak intensity. (Sustiva Stocrin ) F/TAF Emtricitabine + However, the University of Liverpool and its servants or agents shall not be responsible or in any Additional action/monitoring or dosage adjustment is Tenofovir alafenamide way liable for the continued currency of information in this
Load more

Recommended publications
  • <I>Efavirenz</I>, New Therapeutic Agents for AIDS
    CONFERENCE REPORTS 295 CHIMIA 1999. 53. NO.6 CONFERENCE REPORTS Chimia 53 (1999) 295-304 © Neue Schweizerische Chemische Gesellschaft ISSN 0009-4293 Second Swiss/German Meeting on Medicinal Chemistry Fruhjahrsversammlung 1999 der Neuen Schweizerischen Chemischen Gesellschaft (NSCG) 22./23. Marz 1999, Basel Vier Mini-Symposia uber Virologie, Multidrug Resistance, Immunologie und Gene Therapie Organisiert von der Sektion Medizinische Ghemie der NSGG, der Fachgruppe fUr Medizinische Chemie der GDGh und der Basler Chemischen Gesellschatt mit Unterstutzung der Pharmazeutischen Industrie. Report by the Research Team of G. Folkers' 'Correspondence: Prof. Dr. G. Folkers Department of Pharmacy Winterthurerstrasse 190 CH-8057Zi.irich E-Mail: [email protected] Discovery of Indinavir and Efavirenz, New Therapeutic Agents for AIDS Terry A. Lyle, Merck Research Laboratories, West Point, PA, USA For the treatment of HIV infection, two enzymes are of major interest: The HIV-l Protease (PR) and the Reverse- Tran- scriptase (RT). The HIV -Protease, an aspartic-acid pro- tease active as a dimer, is responsible for H 0 the cleavage of polypeptides assembled at o N~' the cell membrane. The inhibition of the Y I( ; N 1\ 0 = H protease-mediated cleavage of the viral "0 o o o precursor polyproteins results in the pro- duction of noninfectious progeny viral par- ticles. The development of lndinavir start- ed with screening a collection of renin inhibitors. A seven-amino-acid analog 1 1 which contains the hydroxyethylene tran- CONFERENCE REPORTS 296 CHIMIA 1999, 53. No.6 prevents the spread of the virus. Different nucleoside inhibitors like AZT, ddI, ddC, d4T and 3TC are already known, but new QH non-nucleoside inhibitors (NNRTI) are U'O developed to decrease the cytotoxicity and N : to improve the selectivity of the viral polymerases vs.
    [Show full text]
  • Antibiotic Treatment in Inflammatory Bowel Disease: Rifaximin, a New Possible Approach
    European Review for Medical and Pharmacological Sciences 1999; 3: 27-30 Review – Antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach P. GIONCHETTI, F. RIZZELLO, A. VENTURI, F. UGOLINI*, M. ROSSI**, P. BRIGIDI**, R. JOHANSSON, A. FERRIERI***, G. POGGIOLI*, M. CAMPIERI Clinica Medica I, Nuove Patologie, Bologna University (Italy) *Istituto di Clinica Chirurgica II, Bologna University (Italy) **Dipartimento di Scienze Farmaceutiche, Bologna University (Italy) ***Direzione Medica Alfa Wassermann, Bologna (Italy) Abstract. – The etiology of inflammatory ported the presence of a breakdown of toler- disease is still unknown, but a body of evidence ance to the normal commensal intestinal flora from clinical and experimental observation indi- in active IBD2-3. Reduction of microflora by cates a role for intestinal microflora in the pathogenesis of this disease. Reduction of mi- antibiotics, bowel rest and fecal diversion de- croflora using antibiotics, bowel rest and fecal creases inflammatory activity in Crohn’s dis- diversion decreases activity in Crohn’s disease ease and to a lesser extent in ulcerative colitis and in ulcerative colitis. Several trials have been (UC). The pathogenetic role of intestinal mi- carried out on the use of antibiotic treatment in croflora is further suggested by the observa- patients with active ulcerative colitis with con- tion that experimental colitis, in germ-free or trasting results. A number of trials have been antibiotic treated animals, is less severe com- carried out using Rifaximin, a non-absorbable broad-spectrum antibiotic, confirming the ab- pared to that inducible in normal animals or sence of systemic bioavalaibility of the drug at times is not inducible at all.
    [Show full text]
  • Veterinary Emergency & Anaesthesia Pfizer
    AVA ECVA & AVEF Thank all their sponsors for this spring edition PARIS 2007 On VETERINARY EMERGENCY & ANAESTHESIA PFIZER MERIAL FORT DODGE BAYER BOEHRINGER MEDISUR COVETO OPTOMED HALLOWELL SCIL JANSSEN SOGEVAL KRUSSE TECHNIBELT MILA TEM The Organisatiors 7th AVEF European Meeting- 10th March 2007-ROISSY 2 AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France AVA PARIS 2007 — Wednesday March 7th RESIDENT DAY RUMINANT ANAESTHESIA Hyatt Regency Hotel, Roissy CDG, France K OTTO, D HOLOPHERNE, G TOUZOT 8.30 REGISTRATIONS 9.00-9.45 Specific anatomo-physiology to consider for ruminant peri-anaesthetic period K OTTO 10.00-10.30 COFFEE BREAK 10.30-11.15 Post-anaesthetic and pain management in ruminants K OTTO 11.30-12.15 Physical restraint and sedation of ruminants D HOLOPHERNE 12.30-1.30 LUNCH 1.30-2.15 Anaesthesia of Lamas & Alpagas G TOUZOT 2.30-3.15 Regional & local anaesthesia for ruminants D HOLOPHERNE 3.30-4.00 COFFEE BREAK 4.00-4.45 Pharmacology and protocols for ruminant anaesthesia G TOUZOT AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France Specific anatomo-physiology to consider for ruminants peri-anaesthetic period Klaus A. Otto Institut für Versuchstierkunde und Zentrales Tierlaboratorium, Medizinische Hochschule Hannover, D-30623 Hannover, Germany The suborder “ruminantia” includes members of the family “bovidae” such as cattle (bos taurus), sheep (ovis spp) and goats (capra spp). Members of the family “camelidae” (camelus spp, llama spp, vicugna spp) belong to the suborder “tylopodia” and therefore are not true ruminants.
    [Show full text]
  • Anaesthesia and Past Use Of
    177 Correspondence were using LSD. It is more popular than other commonly Anaesthesia and past use of used hallucinogens whose quoted incidence of clients are: LSD ketamine 0.1% (super-K/vitamin K.I), psilocybin and psilocin 0.6% (the active alkaloids in the Mexican "magic To the Editor: mushroom"), and 3,4 methylenedioxymethamphetamine We report the case of a 43-yr-old lady who was admitted ~MDMA" 1% (ecstasy). The effects of the concurrent to the Day Surgery Unit for release of her carpal tunnel ingestion of LSD on anaesthesia are well described. 2-4 retinaculum. During the preoperative visit, she reported The long-term effects of the past use of LSD are largely no intercurrent illnesses, drug therapy or allergies. She unknown. We wonder if the hallucinations experienced did say, however, that she was frightened of general anaes- by our patient during anaesthesia were due to her LSD thesia, since she had experienced terrifying dreams during intake many years before. We would be interested to surgery under general anaesthesia on three occasions dur- know if others have had experience anaesthetising patients ing the previous ten years. On further questioning, she who are past users of phencyclidine-derived drugs. admitted that she had used lysergic acid diethylamide (LSD) during the late 1960's, the last occasion being 1968 Geoffrey N. Morris MRCGPFRCA when she had experienced characterstic hallucinations. Patrick T. Magee MSe FRCA She had not experienced hallucinations in the ensuing Anaesthetic Department years, except on the surgical occasions mentioned. Royal United Hospital One of the three previous operations had been per- Combe Park formed at our hospital and the anaesthetic record was Bath BA1 3NG checked.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Formulary Additions
    JUNE 2016 FORMULARY ADDITIONS MELOXICAM (MOBIC®) Rationale for Addition: Meloxicam is a once daily NSAID used for the treatment of rheumatoid arthritis and osteoarthritis. Meloxicam will provide another oral NSAID option to Celecoxib for patients who are being discharged home and whose insurance does not cover celecoxib. Adverse Effects: abdominal pain, diarrhea, dyspepsia, flatulence, nausea, edema, influenza-like symptoms, dizziness, headache, rash Contraindications: peri-operative pain in setting of coronary artery bypass graft surgery Drug Interactions: other NSAIDS, antiplatelet agents, calcium polysterene sulfonate, cyclosporine, digoxin, lithium, methotrexate, vancomycin, vitamin K antagonist, corticosteroids Dosage & Administration: meloxicam 7.5 mg PO daily, some patients my experience some benefit by increasing to 15 mg PO daily Renal Impairment: not recommended in patients with renal function ≤ 20 mL/min Dosage Form & Cost: meloxicam 7.5 mg tablet $0.02/day meloxicam 15 mg $0.03/day IVABRADINE (CORLANOR®) *Restrictions*: restricted to cardiology only for initiation of therapy Rationale for Addition: Ivabradine blocks the funny current leading to a reduction in heart rate at the sinoatrial node. Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable symptomatic chronic heart failure with LVEF ≤ 35% who are in sinus rhythm with resting heart rate (HR) ≥ 70 beats per minute and either on maximally tolerated doses of β-blockers or have a contraindication to β-blockers.
    [Show full text]
  • Evidence for the Involvement of Spinal Cord 1 Adrenoceptors in Nitrous
    Anesthesiology 2002; 97:1458–65 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Evidence for the Involvement of Spinal Cord ␣ 1 Adrenoceptors in Nitrous Oxide–induced Antinociceptive Effects in Fischer Rats Ryo Orii, M.D., D.M.Sc.,* Yoko Ohashi, M.D.,* Tianzhi Guo, M.D.,† Laura E. Nelson, B.A.,‡ Toshikazu Hashimoto, M.D.,* Mervyn Maze, M.B., Ch.B.,§ Masahiko Fujinaga, M.D.ʈ Background: In a previous study, the authors found that ni- opioid peptide release in the brain stem, leading to the trous oxide (N O) exposure induces c-Fos (an immunohisto- 2 activation of the descending noradrenergic inhibitory chemical marker of neuronal activation) in spinal cord ␥-ami- nobutyric acid–mediated (GABAergic) neurons in Fischer rats. neurons, which results in modulation of the pain–noci- 1 In this study, the authors sought evidence for the involvement ceptive processing in the spinal cord. Available evi- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/6/1458/337059/0000542-200212000-00018.pdf by guest on 01 October 2021 ␣ of 1 adrenoceptors in the antinociceptive effect of N2O and in dence suggests that at the level of the spinal cord, there activation of GABAergic neurons in the spinal cord. appear to be at least two neuronal systems that are Methods: Adult male Fischer rats were injected intraperitone- involved (fig. 1). In one of the pathways, activation of ally with ␣ adrenoceptor antagonist, ␣ adrenoceptor antago- 1 2 ␣ nist, opioid receptor antagonist, or serotonin receptor antago- the 2 adrenoceptors produces either direct presynaptic nist and, 15 min later, were exposed to either air (control) or inhibition of neurotransmitter release from primary af- 75% N2O.
    [Show full text]
  • Vademecum Agrovet Market Animal Health
    Vademecum Agrovet Market Animal Health We are a Peruvian company focused on the development, production and commercialization of veterinary products, driving its technical and creative development to meet the needs of veterinarians and stock farmers with unique products of high quality. www.agrovetmarket.com Mission l Products of Unique Class Provide veterinary, nutritional and farmaceutical products of unique class; developed in a creative and innovative way, under high standards of quality that allow us to reach international markets and consolidate locally through the formal stablishment of strategical alliances. Antibiotics Line of large animals am Line of companion animals ac Line of poultry and swine av www.agrovetmarket.com Antibiotics ® Agrogenta 11 | Vetigen 11 Injectable Solution Broad-spectrum aminoglycoside Composition: Gentamicin (as sulphate) 110 mg, excipients q.s. ad 1 mL. Indications: Treatment and prevention of infections caused by microorganisms sensitive to gentamicin (of the urogenital, respiratory and gastrointestinal systems). Also useful in cases of mastitis, metritis, post-operatory and cutaneous infections, septicemias, among others.. Dosage and Administration: Cattle, horse, sheep, goat, swine, camelid: 1 mL/27.5 kg of b.w.; young animals, dogs and cats: 1 mL/14 kg; poultry: 0.1 mL/1.4 kg; every 24 hours for 3 to 5 consecutive days by subcutaneous or intramuscular route. Intrauterine or intra-mammary route: Cows: 2 mL diluted in 20 mL of physiological saline solution for 3 to 5 days. Mares: 20 mL diluted in 200 - 500 mL of physiological saline solution for 3 to 5 days (only intrauterine route). Commercial Presentation: Bottle x 100 mL and 250 mL.
    [Show full text]
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • 5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate
    5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum Grégory Porras, M.S., Vincenzo Di Matteo, Ph.D., Claudia Fracasso, B.S., Guillaume Lucas, Ph.D., Philippe De Deurwaerdère, Ph.D., Silvio Caccia, Ph.D., Ennio Esposito, M.D., Ph.D., and Umberto Spampinato, M.D., Ph.D. In vivo microdialysis and single-cell extracellular neuron firing rate in both the ventral tegmental area and recordings were used to assess the involvement of the substantia nigra pars compacta was unaffected by SR serotonin2A (5-HT2A) and serotonin2C/2B (5-HT2C/2B) 46349B (0.1 mg/kg i.v.) but significantly potentiated by SB receptors in the effects induced by amphetamine and 206553 (0.1 mg/kg i.v.). These results show that 5-HT2A morphine on dopaminergic (DA) activity within the and 5-HT2C receptors regulate specifically the activation of mesoaccumbal and nigrostriatal pathways. The increase in midbrain DA neurons induced by amphetamine and DA release induced by amphetamine (2 mg/kg i.p.) in the morphine, respectively. This differential contribution may nucleus accumbens and striatum was significantly reduced be related to the specific mechanism of action of the drug by the selective 5-HT2A antagonist SR 46349B (0.5 mg/kg considered and to the neuronal circuitry involved in their s.c.), but not affected by the 5-HT2C/2B antagonist SB effect on DA neurons. Furthermore, these results suggest 206553 (5 mg/kg i.p.). In contrast, the enhancement of that 5-HT2C receptors selectively modulate the impulse accumbal and striatal DA output induced by morphine (2.5 flow–dependent release of DA.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Bonviva, INN- Ibandronic Acid
    European Medicines Agency London, 1 September 2005 Doc.Ref.: EMEA/278873/2005 Bonviva International Nonproprietary Name: Ibandronic acid Following the procedure EMEA/H/C/501/X/01 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: [email protected] http://www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged 1 SCIENTIFIC DISCUSSION 1.1 Introduction and rationale The MAH submitted an extension application under Annex II, point 2 iii to Commission Regulation (EC) No 1085/2003 to request the approval of a 150 mg tablet as a monthly dosing regimen of ibandronate only for the indication of “treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures”. This claim is based on the results of a phase III study MOBILE (BM16549) comparing 100 and 150 mg once monthly to 2.5 mg once daily. Due to the inconveniences associated with intake of oral bisphosphonates (i.e. fasting conditions, frequent upper gastrointestinal intolerance) that may result in poor compliance, it was considered desirable to develop a more convenient drug formulation. Hence a 150 mg once monthly oral regimen is expected to offer greater convenience to postmenopausal women when compared to the currently approved 2.5mg once daily tablet. The development programme No new pre-clinical pharmacodynamic and pharmacokinetic studies have been performed in addition to those included in the previous submission for ibandronate 2.5 mg daily oral tablets.
    [Show full text]